Roundtable Roundup: First and Second Choices for Frontline RCC Therapy

In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients with prostate cancer.

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

During a Case-Based Roundtable® event, Sagar D. Sardesai, MD, moderated a discussion on using antibody-drug conjugates and managing their toxicities in patients with metastatic breast cancer.

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

Evidence suggests that extranodal extension on radiological imaging is a negative prognostic factor in head and neck cancer, but diagnostic criteria and terminology have been unclear.

Debaters Andres Chang, MD, PhD, and Jean Louise Koff, MD, MS, led the verbal battle at the Debates and Didactics in Hematology and Oncology Conference held from July 25 to 28, 2024, in Sea Island, Georgia.